CN116847869A - 用于治疗和预防1型糖尿病的方法和组合物 - Google Patents

用于治疗和预防1型糖尿病的方法和组合物 Download PDF

Info

Publication number
CN116847869A
CN116847869A CN202180077223.6A CN202180077223A CN116847869A CN 116847869 A CN116847869 A CN 116847869A CN 202180077223 A CN202180077223 A CN 202180077223A CN 116847869 A CN116847869 A CN 116847869A
Authority
CN
China
Prior art keywords
insulin
peptide
mammal
diabetes
related peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180077223.6A
Other languages
English (en)
Chinese (zh)
Inventor
M·S·莫里斯
R·迪波洛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
American Merchant Dr Mary Morris Associates LLC
St Louis University
Original Assignee
American Merchant Dr Mary Morris Associates LLC
St Louis University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Merchant Dr Mary Morris Associates LLC, St Louis University filed Critical American Merchant Dr Mary Morris Associates LLC
Publication of CN116847869A publication Critical patent/CN116847869A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202180077223.6A 2020-10-08 2021-10-05 用于治疗和预防1型糖尿病的方法和组合物 Pending CN116847869A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063089122P 2020-10-08 2020-10-08
US63/089,122 2020-10-08
PCT/US2021/053537 WO2022076385A1 (en) 2020-10-08 2021-10-05 Methods and compositions for the treatment and prevention of type 1 diabetes

Publications (1)

Publication Number Publication Date
CN116847869A true CN116847869A (zh) 2023-10-03

Family

ID=81126224

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180077223.6A Pending CN116847869A (zh) 2020-10-08 2021-10-05 用于治疗和预防1型糖尿病的方法和组合物

Country Status (7)

Country Link
US (1) US20240041986A1 (https=)
EP (1) EP4225352A4 (https=)
JP (1) JP2023544832A (https=)
CN (1) CN116847869A (https=)
AU (1) AU2021356578A1 (https=)
CA (1) CA3193994A1 (https=)
WO (1) WO2022076385A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3159054A1 (en) * 2019-12-06 2021-06-10 Mary S. MORRIS Methods and compositions for the treatment and prevention of type 1 diabetes

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1409640A (zh) * 1999-12-16 2003-04-09 伊莱利利公司 稳定性改善的多肽组合物
US7279457B2 (en) * 2004-03-12 2007-10-09 Biodel, Inc. Rapid acting drug delivery compositions
US20090023630A1 (en) * 2005-01-31 2009-01-22 Jan Wouter Drijfhout Methods and Means for Use in Diagnostics and Treatment of Diabetes
AU2011202239C1 (en) * 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
US9381247B2 (en) * 2012-04-16 2016-07-05 Biodel Inc. Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain
JP2020143105A (ja) * 2014-01-09 2020-09-10 サノフイＳａｎｏｆｉ インスリンアスパルトの安定化された医薬製剤
US10905727B2 (en) * 2016-01-14 2021-02-02 Intrexon Actobiotics N.V. Compositions and methods for the treatment of type 1 diabetes
US20200087374A1 (en) * 2017-02-06 2020-03-19 Resiliun B.V. Interaction between c-peptides and elastin receptor, a model for understanding vascular disease
EP3589271A4 (en) * 2017-02-28 2021-01-06 Biolingus IP LLC OIL BASED FORMULATIONS FOR SUBLINGUAL AND BUCCAL ADMINISTRATION
CN110662551B (zh) * 2017-06-01 2023-07-18 伊莱利利公司 速效胰岛素组合物
EP3823644A4 (en) * 2018-07-22 2022-06-08 Minovia Therapeutics Ltd. MITOCHONDRIAL AUGMENTATION THERAPY OF PANCREATIC DISEASES
CA3159054A1 (en) * 2019-12-06 2021-06-10 Mary S. MORRIS Methods and compositions for the treatment and prevention of type 1 diabetes

Also Published As

Publication number Publication date
EP4225352A1 (en) 2023-08-16
WO2022076385A1 (en) 2022-04-14
JP2023544832A (ja) 2023-10-25
CA3193994A1 (en) 2022-04-14
AU2021356578A9 (en) 2023-07-13
AU2021356578A1 (en) 2023-05-11
EP4225352A4 (en) 2024-01-10
US20240041986A1 (en) 2024-02-08

Similar Documents

Publication Publication Date Title
EP1988100B1 (en) Derivatives of glucagon-like peptide-2 and their therapeutic use
US8481490B2 (en) Method of reducing plasma amylase and/or plasma lipase in patients with pancreatitis
KR102460198B1 (ko) 비만 치료를 위한 글루카곤 및 glp-1 공동-작용제
US11447555B2 (en) Methods for treating type 1 diabetes using glucagon receptor antagonistic antibodies
KR20100080519A (ko) 프로섬 펩타이드 및 이의 유사체의 조성물 및 이의 이용 방법
ZA200109925B (en) GLP-1 as a diagnostic test to determine beta-cell function and the presence of the condition of IGT and type-II diabetes.
CN115151273A (zh) 用于治疗和预防1型糖尿病的方法和组合物
CN116847869A (zh) 用于治疗和预防1型糖尿病的方法和组合物
JP2008535797A (ja) ヒトレプチン由来のポリペプチドとその使用
CN105492459A (zh) 用于治疗糖尿病的修饰的ingap肽
US20090197800A1 (en) Insulin Receptor Binding Peptides with Non-Insulin Gene Activation Profiles and Uses Thereof
Brandt Synthesis and characterization of insulin receptor partial agonists as a route to improved diabetes therapy
HK40078570B (en) Methods and compositions for the prevention of type 1 diabetes
HK40078570A (en) Methods and compositions for the prevention of type 1 diabetes
EP1819354B1 (en) Methods and compounds for treating diabetes
KR20220110506A (ko) 비만 치료를 위한 글루카곤 및 glp-1 공동-작용제를 사용하는 조합 치료법
CN119192298A (zh) 一类双位点偶联脂肪酸的BimBH3类似物及其制备方法与应用
CN120051293A (zh) 用于治疗糖尿病或肥胖症的组合物
HK1153482A (en) Glucagon-like peptide-2 derivatives and their therapeutic use
HK1125653A (en) Derivatives of glucagon-like peptide-2 and their therapeutic use
HK1149720A (en) Glucagon-like peptide-2 and its therapeutic use

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination